Could a popular Weight-Loss drug help people with rare genetic obesity?
NCT ID NCT06380426
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study follows 175 adolescents and adults with monogenic obesity—a rare form caused by specific gene changes—who are taking semaglutide (Ozempic/Wegovy). Researchers will track weight and BMI changes over 4 years to see if the drug helps control weight in this group. The goal is to provide real-world evidence for using semaglutide in people who often don't respond well to diet, exercise, or surgery.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- semaglutide (Ozempic/Wegovy)
- What this could lead to
- If successful, this could show that semaglutide is an effective treatment for managing weight in people with rare genetic obesity.
- What could go wrong
- This is an observational study, not a controlled trial, so results may be less reliable. It is also small (175 people) and focused on a rare condition, so findings may not apply broadly.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MONOGENIC OBESITY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
CHU Pitié Salpêtrière - APHP
RECRUITINGParis, 75013, France
-
Centre de référence Syndrome de Prader-Willi et autres obésités avec troubles du comportement alimentaire (PRADORT). Service de Nutrition, GH Pitié-Salpêtrière, APHP
NOT_YET_RECRUITINGParis, 75013, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.